| 22-01-07 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 22-01-06 | Notification about results of final buy-back of shares | AQ |
| 21-12-30 | Notification about final share buy-back | AQ |
| 21-12-28 | Correction: Regarding results of a share buy-back offer | AQ |
| 21-12-28 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 2025-12-31 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 2009-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 2021-06-18 | |
Janis Buks
CHM | Chairman | - | 2022-08-31 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 8/4/21 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +7.19% | +2.67% | - | - | 148M | ||
| +0.56% | -2.51% | +22.30% | +68.07% | 48.95B | ||
| +3.09% | +7.65% | +60.81% | +132.38% | 39.36B | ||
| +1.16% | +0.65% | -0.73% | +20.61% | 12.39B | ||
| -1.34% | -0.81% | +18.59% | +68.82% | 11.76B | ||
| +1.53% | -0.38% | +30.75% | +134.53% | 9.14B | ||
| +0.21% | +3.15% | +18.38% | +33.96% | 7.05B | ||
| +1.61% | -4.86% | +36.73% | -14.17% | 6.86B | ||
| -0.09% | +3.19% | +11.58% | +176.99% | 6.7B | ||
| +0.79% | +3.84% | -29.57% | +15.81% | 5.67B | ||
| Average | +1.49% | -0.26% | +18.76% | +70.78% | 16.43B | |
| Weighted average by Cap. | +1.22% | -0.33% | +28.85% | +82.87% |
Employees
2,191
Sector
Pharmaceuticals
















